Objective: To determine whether etanercept therapy enables long-term psoriasis patients to discontinue systemic psoriatic therapy. Methods: Charts from psoriatic patients on etanercept therapy seen at the Department o...Objective: To determine whether etanercept therapy enables long-term psoriasis patients to discontinue systemic psoriatic therapy. Methods: Charts from psoriatic patients on etanercept therapy seen at the Department of Dermatology and Dermatolgic Surgery, University of Miami, Miami, FL, USA, between June 2002 and October 2003, were evaluated retrospectively. The duration of disease, adverse events to “standard”systemic psoriatic therapy, and current therapy were reviewed. IRB: 03/582C. Results: A large proportion of patients (73.5%) were able to decrease or discontinue their traditional systemic agent while on etanercept. Conclusions: Etanercept is a safe and effective therapy in chronic moderate to severe psoriasis. In patients who are receiving systemic therapy for their disease and alternative therapy is warranted, etanercept can be added with the aim to discontinue the other systemic agents.展开更多
Scleromyxedema is a rare dermatological disorder marked by Wide spread symmetric 2-to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs. The most common extracu...Scleromyxedema is a rare dermatological disorder marked by Wide spread symmetric 2-to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs. The most common extracutaneous manifestation of scleromyxedema is a benign plasma cell dyscrasia. Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects. We report a severe case of scleromyxedema who had marked improvement when treated with thalidomide.展开更多
文摘Objective: To determine whether etanercept therapy enables long-term psoriasis patients to discontinue systemic psoriatic therapy. Methods: Charts from psoriatic patients on etanercept therapy seen at the Department of Dermatology and Dermatolgic Surgery, University of Miami, Miami, FL, USA, between June 2002 and October 2003, were evaluated retrospectively. The duration of disease, adverse events to “standard”systemic psoriatic therapy, and current therapy were reviewed. IRB: 03/582C. Results: A large proportion of patients (73.5%) were able to decrease or discontinue their traditional systemic agent while on etanercept. Conclusions: Etanercept is a safe and effective therapy in chronic moderate to severe psoriasis. In patients who are receiving systemic therapy for their disease and alternative therapy is warranted, etanercept can be added with the aim to discontinue the other systemic agents.
文摘Scleromyxedema is a rare dermatological disorder marked by Wide spread symmetric 2-to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs. The most common extracutaneous manifestation of scleromyxedema is a benign plasma cell dyscrasia. Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects. We report a severe case of scleromyxedema who had marked improvement when treated with thalidomide.
